IMMATICS is a leader in developing targeted therapies that enable the immune system to recognize and destroy cancer cells. Their innovative approaches, based on personalized TCR-T cell therapies ...

Immatics is a clinical-stage biopharmaceutical company at the forefront of the discovery and development of T cell–based immunotherapies to treat cancer. Its mission is to open new therapeutic ...

Immatics (IMTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...